Predicted to enable protein tyrosine phosphatase activity. Involved in inner ear development. Predicted to be active in nucleus. Human ortholog(s) of this gene implicated in autosomal dominant nonsyndromic deafness 10; congestive heart failure; dilated cardiomyopathy; dilated cardiomyopathy 1J; and sensorineural hearing loss. Orthologous to human EYA4 (EYA transcriptional coactivator and phosphatase 4); INTERACTS WITH alpha-Zearalanol; atrazine; bisphenol A.
[Zeranol co-treated with perfluorooctanoic acid] results in decreased expression of EYA4 mRNA and [Zeranol co-treated with perfluorooctanoic acid] results in increased expression of EYA4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EYA4 mRNA
[Zeranol co-treated with perfluorooctanoic acid] results in decreased expression of EYA4 mRNA and [Zeranol co-treated with perfluorooctanoic acid] results in increased expression of EYA4 mRNA
[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of EYA4 mRNA and [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of EYA4 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EYA4 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EYA4 mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EYA4 mRNA